Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Samuel B Huxley
Observed names:
S Huxley,
Sam Huxley,
Samuel B. Huxley,
Samuel Huxley
Institution:
Mayo Clinic
Observed institution:
Mayo Clinic
ORCID:
0009-0002-3912-0520
Observed ORCID:
0009-0002-3912-0520
OpenAlex ID:
A5071035401
Incidence and outcomes of high bleeding risk patients with type 1 and type 2 myocardial infarction in a community-based cohort: Application of the Academic Research Consortium High Bleeding Risk Criteria
2023
·
Thomas J. Breen
, Claire E. Raphael
, et al.
·
International Journal of Cardiology
·
5
PDF
Genotype-Guided P2Y12 Inhibitor Monotherapy Within 7 Days of Percutaneous Coronary Intervention in High Bleeding Risk Patients
2024
·
Brenden S. Ingraham
, Samuel B. Huxley
, et al.
·
Mayo Clinic Proceedings
·
3
Cost analysis of CYP2C19 genetic testing in percutaneous coronary intervention patients
2024
·
Samuel Huxley
, James Moriarty
, et al.
·
The Pharmacogenomics Journal
·
3
Rapamycin in Frail Older Patients With Heart Failure With Preserved Ejection Fraction
2026
·
Conor M. Lane
, Jericha Mill
, et al.
·
Mayo Clinic Proceedings
Genotype-guided P2y12 Inhibitor Monotherapy Within 7 Days of Percutaneous Coronary Intervention in High Bleeding Risk Patients: the Champ Trial - a Pilot Study and Safety Assessment
2024
·
Brenden Ingraham
, Sam Huxley
, et al.
·
Journal of the American College of Cardiology
Direct cost analysis of genetic testing for CYP2C19*2 and *3 loss of function variants in percutaneous coronary intervention patients
2022
·
S Huxley
, N Pereira
, et al.
·
European Heart Journal
Show more works
View as search
Works count:
6
Citation count:
11
H-index:
3
I10-index:
Year
Topic
Type